{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:36:34Z","timestamp":1732685794935,"version":"3.28.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10261-y","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T19:39:28Z","timestamp":1732649968000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and booster vaccine effectiveness of the Omicron variant"],"prefix":"10.1186","volume":"24","author":[{"given":"Lijun","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biye","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"10261_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924\u201344.","journal-title":"Lancet"},{"issue":"1","key":"10261_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","volume":"29","author":"WY Chi","year":"2022","unstructured":"Chi WY, Li YD, Huang HC, et al. COVID-19 vaccine update: vaccine, effectiveness, SARS-CoV-2 variants, boosters, adverse, effects, and immune correlates of protection. J Biomed Sci. 2022;29(1):82.","journal-title":"J Biomed Sci"},{"issue":"2","key":"10261_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1056\/NEJMoa2116063","volume":"386","author":"ES Rosenberg","year":"2022","unstructured":"Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386(2):116\u201327.","journal-title":"N Engl J Med"},{"issue":"4","key":"10261_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340\u201350.","journal-title":"N Engl J Med"},{"issue":"7898","key":"10261_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2021","unstructured":"Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021;602(7898):671\u20135.","journal-title":"Nature"},{"issue":"6","key":"10261_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/tmi.13752","volume":"27","author":"M-A Davies","year":"2022","unstructured":"Davies M-A, Kassanjee R, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop Med Int Health. 2022;27(6):564\u201373.","journal-title":"Trop Med Int Health"},{"key":"10261_CR7","doi-asserted-by":"publisher","first-page":"917e24","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917e24.","journal-title":"Nat Med"},{"key":"10261_CR8","doi-asserted-by":"publisher","first-page":"1896e8","DOI":"10.1001\/jama.2021.4388","volume":"325","author":"VV Edara","year":"2021","unstructured":"Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA. 2021;325:1896e8.","journal-title":"JAMA"},{"key":"10261_CR9","doi-asserted-by":"publisher","first-page":"142e6","DOI":"10.1038\/s41586-021-03471-w","volume":"593","author":"S Cele","year":"2021","unstructured":"Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593:142e6.","journal-title":"Nature"},{"issue":"18","key":"10261_CR10","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","volume":"386","author":"YM Bar-On","year":"2022","unstructured":"Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712\u201320.","journal-title":"N Engl J Med"},{"issue":"17","key":"10261_CR11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","volume":"386","author":"O Magen","year":"2022","unstructured":"Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603\u201314.","journal-title":"N Engl J Med"},{"key":"10261_CR12","unstructured":"Office of the C. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. 2022; 387(17): 1603-14."},{"key":"10261_CR13","unstructured":"Med HKU. Modelling HK\u2019s fifth wave of Omicron BA.2. Available website: https:\/\/www.med.hku.hk\/en\/news\/press\/-\/media\/HKU-Med-Fac\/News\/slides\/20220210-wave_5_omicron_final.ashx (Accessed date: January 18, 2024)."},{"issue":"1","key":"10261_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","volume":"20","author":"B Zeng","year":"2022","unstructured":"Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against ASRS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200.","journal-title":"BMC Med"},{"issue":"7","key":"10261_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"JM Ferdinands","year":"2022","unstructured":"Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255\u201363.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10261_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063\u201371.","journal-title":"Nat Med"},{"issue":"7898","key":"10261_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657\u201363.","journal-title":"Nature"},{"issue":"7898","key":"10261_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676\u201381.","journal-title":"Nature"},{"issue":"13","key":"10261_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"V Hall","year":"2022","unstructured":"Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207\u201320.","journal-title":"N Engl J Med"},{"issue":"10328","key":"10261_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924\u201344.","journal-title":"Lancet"},{"key":"10261_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/d41586-021-02532-4","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin E. COVID vaccine immunity is waning: how much does that matter? Nature. 2021;597:606\u201307.","journal-title":"Nature"},{"issue":"1","key":"10261_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s15010-021-01664-z","volume":"50","author":"A Hamady","year":"2022","unstructured":"Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2022;50(1):11\u201325.","journal-title":"Infection"},{"key":"10261_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393\u2013400.","journal-title":"N Engl J Med"},{"key":"10261_CR24","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093\u2013100.","journal-title":"Lancet"},{"key":"10261_CR25","doi-asserted-by":"crossref","unstructured":"Andrews N, Stowe J, Kirsebom F et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related. Symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831\u20137.","DOI":"10.1038\/s41591-022-01699-1"},{"issue":"7","key":"10261_CR26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41591-022-01832-0","volume":"28","author":"R Arbel","year":"2022","unstructured":"Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28(7):1486\u201390.","journal-title":"Nat Med"},{"issue":"11","key":"10261_CR27","doi-asserted-by":"publisher","first-page":"e747","DOI":"10.1016\/S2665-9913(21)00312-X","volume":"3","author":"BV Maramattom","year":"2021","unstructured":"Maramattom BV, Philips G, Thomas J, et al. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021;3(11):e747\u20139.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10261_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ana.26143","volume":"90","author":"BV Maramattom","year":"2021","unstructured":"Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barre Syndrome following ChAdOx1-S\/nCoV-19 vaccine. Ann Neurol. 2021;90(2):312\u20134.","journal-title":"Ann Neurol"},{"key":"10261_CR29","doi-asserted-by":"publisher","unstructured":"Bai Y, Du Z, Wang L, et al. Public health impact of Paxlovid as treatment for COVID-19, United States. Emerg Infect Dis. 2024;30(2). https:\/\/doi.org\/10.3201\/eid3002.230835.","DOI":"10.3201\/eid3002.230835"},{"key":"10261_CR30","unstructured":"Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for molnupiravir. https:\/\/www.fda.gov\/media\/155054\/download (2021)."},{"issue":"3","key":"10261_CR31","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10261_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40121-023-00760-x","volume":"12","author":"C Weng","year":"2023","unstructured":"Weng C, Xie R, Han G, et al. Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients. Infect Dis Ther. 2023;12(2):649\u201362.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"10261_CR33","doi-asserted-by":"publisher","first-page":"e28947","DOI":"10.1002\/jmv.28947","volume":"95","author":"H Yang","year":"2023","unstructured":"Yang H, Wang Z, Jiang C, et al. Oral azvudine for mild-to\u2010moderate COVID\u201019 in high risk, nonhospitalized adults: results of a real\u2010world study. J Med Virol. 2023;95(7):e28947.","journal-title":"J Med Virol"},{"issue":"1","key":"10261_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV\u20102 vaccines on symptomatic COVID\u201019 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35\u201345.","journal-title":"JAMA"},{"issue":"1","key":"10261_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV\u20102 vaccine, BBIBP\u2010CorV: a randomised, double\u2010blind, placebo\u2010controlled, phase 1\/2 trial. Lancet Infect Dis. 2021;21(1):39\u201351.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10261_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV\u20102 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951\u201360.","journal-title":"JAMA"},{"issue":"5","key":"10261_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMc2119270","volume":"386","author":"S Collie","year":"2022","unstructured":"Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494\u20136.","journal-title":"N Engl J Med"},{"issue":"19","key":"10261_CR38","doi-asserted-by":"publisher","first-page":"e2001435","DOI":"10.1002\/advs.202001435","volume":"7","author":"Z Ren","year":"2020","unstructured":"Ren Z, Luo H, Yu Z, et al. A randomized, open-Label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID\u201019, a pilot study. Adv Sci. 2020;7(19):e2001435.","journal-title":"Adv Sci"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10261-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T20:02:37Z","timestamp":1732651357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10261"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10261-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Review Committee of the Beijing Hospital of Traditional Chinese Medicine, Capital Medical University provided approval for this study (No: 2023BL02-016-01). Patients\u2019 personal identifying information was anonymized to ensure privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1351"}}